Meet us at the St. Francis, and bring your own damn water! Happy Morgan's Eve, everyone. If you’re like FOTF, you’ve been preparing ...

One of the best things about having time to sit down with a company's executive team and discuss matters such as pipeline and business s...

With what seemed to be stellar results from the ARISTOTLE trial, showing the first superiority over warfarin on bleeding and mortality f...

Roche had a number of pithy taglines to splash around its oncology business review at ASCO: "we take cancer personally," or wi...

In tandem with a 10-company effort launched in September to resolve clinical development hurdles, three pharmas are coming together to e...

Wall Street analyst Raghuram Selveraju likens today’s drug-development landscape to the changes seen in men’s professional tennis betwee...

The big funding news this fortnight doesn’t come from public or private investors, it comes from taxpayers. As " The Pink Sheet ...

In Tuesday's New York Times, biotech writer Andrew Pollack has an overview of the work in progress to reach a cure for HIV, a story t...

By Aidan Finley , Consultant, Health Advances We are all well aware that oncology is rapidly undergoing significant changes. Encouraged...